JoVE Encyclopedia of Experiments
Cancer Research
0 views • 3:36 min • April 30th, 2023
- Pretargeted radioimmunotherapy or PRIT utilizes an immunoconjugate or an antibody construct that binds to a radioactive ligand while presenting a high affinity towards a tumor specific cell surface antigen. To pre-target, take the desired concentration of these antibodies in a syringe treated with serum albumin proteins. Serum treatment prevents the binding of these antibodies to the syringe walls.
Next, place a colorectal tumor-bearing mouse model under a heat lamp to dilate its tail vein. Inject the antibodies into the dilated vein. As these immunoconjugates reach the tumor site, their high affinity towards the tumor-specific cell surface antigen promotes their accumulation within the tissue.
Subsequently, take an appropriate dose of the radioactive ligand. Administer the radioligand into the dilated tail vein of the pre-targeted mouse. Once these molecules reach the tumor site, they combine with the antibodies. The high dose of radiation emitted during the radioactive decay of these ligands kills the targeted tumor while minimizing exposure to normal cells.
In the following protocol, we will show pretargeted radioimmunotherapy using trans-cyclooctene-modified antibodies and Lu
View the full transcript and gain access to thousands of scientific videos